| 0.005 0 (0%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.05 | 1-year : | 0.08 |
| Resists | First : | 0.04 | Second : | 0.07 |
| Pivot price | 0.01  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0.02 |
| MA(100) : | 0.04 |
MA(250) : | 1.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0.2 |
D(3) : | 0 |
| RSI | RSI(14): 24.5 |
|||
| 52-week | High : | 10.38 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VINC ] has closed above bottom band by 23.7%. Bollinger Bands are 111.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Thu, 17 Apr 2025
Vincerx Pharma Announces Suspension and Intent to Delist Common Stock from Nasdaq - Nasdaq
Thu, 17 Apr 2025
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - GlobeNewswire
Thu, 17 Apr 2025
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
Tue, 08 Apr 2025
Financially struggling drugmaker's potential rescue falls apart. It now will wind down - San Francisco Business Times - The Business Journals
Tue, 08 Apr 2025
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.67e+006 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 192 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.487e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -197.6 % |
| Return on Equity (ttm) | -3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 81.2 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.02 |
| Dividend | 0 |
| Forward Dividend | 137200 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|